TriangleNCT00795769 · STUDY IN CONTEXT
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma-pediatric
- nct id
- NCT00795769
- trial label
- Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 1
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma-pediatric
- nct id
- NCT00795769
- outcome key
- om-0000
- source section id
- NCT00795769-om-0000
- source outcome index
- 0
- endpoint
- Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)
- endpoint definition
- Nausea Multinational Association of Supportive Care in Cancer Antiemesis Tool™ (MAT). Increased MAT scores represent worse outcome (score 0-10). Vomiting represented as present or absent.
- time origin
- Baseline up to 120 minutes
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma-pediatric
- nct id
- NCT00795769
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Ondansetron Therapy
- regimen
- Patients receive 16mg ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation. ondansetron: Given IV survey administration: Correlative studies management of therapy complications: Ondansetron IV
- analyzed count
- 49
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00795769-om-0000#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma-pediatric
- nct id
- NCT00795769
- harm key
- EG000
- source section id
- NCT00795769-ae
- event group key
- EG000
- event group label
- Ondansteron Therapy
- serious affected
- 0
- serious at risk
- 49
- other affected
- 18
- other at risk
- 49
- frequency threshold
- 5
- collection period
- 11 months between August 2008-June 2009
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice